Conjugation to macromolecular carriers is a proven strategy for improving the pharmacokinetics of drugs, with many stable polyethylene glycol conjugates having reached the market. Stable conjugates suffer several limitations: loss of drug potency due to conjugation, confining the drug to the extracellular space, and the requirement for a circulating conjugate. Current research is directed toward overcoming such limitations through releasable conjugates in which the drug is covalently linked to the carrier through a cleavable linker. Satisfactory linkers that provide predictable cleavage rates tunable over a wide time range that are useful for both circulating and noncirculating conjugates are not yet available. We describe such conjugation linkers on the basis of a nonenzymatic β-elimination reaction with preprogrammed, highly tunable cleavage rates. A set of modular linkers is described that bears a succinimidyl carbonate group for attachment to an amine-containing drug or prodrug, an azido group for conjugation to the carrier, and a tunable modulator that controls the rate of β-eliminative cleavage. The linkers provide predictable, tunable release rates of ligands from macromolecular conjugates both in vitro and in vivo, with half-lives spanning from a range of hours to >1 y at physiological pH. A circulating PEG conjugate achieved a 56-fold half-life extension of the 39-aa peptide exenatide in rats, and a noncirculating s.c. hydrogel conjugate achieved a 150-fold extension. Using slow-cleaving linkers, the latter may provide a generic format for once-a-month dosage forms of potent drugs. The releasable linkers provide additional benefits that include lowering C max and pharmacokinetic coordination of drug combinations. metronomic chemotherapy | implant M any drugs and drug candidates are suboptimal or ineffective because of a short duration of action. For example, peptides and proteins with promising therapeutic value often have serum half-lives of only minutes to hours. One solution to this problem involves conjugation to carriers such as polyethylene glycol (PEG), the Fc portion of IgG, serum albumin, and other longlived macromolecules. The large carriers retard kidney filtration and hence increase plasma half-life of the attached drug. Much success has been realized thus far with PEG as the macromolecular carrier. PEG is nontoxic and nonimmunogenic, and the plasma half-life is a function of hydrodynamic size. Conjugation of drugs to PEG with molecular mass ∼40 kDa has been successfully used with peptides, nucleic acids, and small molecules and can afford half-lives of up to ∼7 d in humans; as of 2011, 10 PEGylated peptide-based drugs were approved by the Food and Drug Administration (FDA) and ∼40 were in clinical trials (1, 2).
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metronomic chemotherapy | implant M any drugs and drug candidates are suboptimal or ineffective because of a short duration of action. For example, peptides and proteins with promising therapeutic value often have serum half-lives of only minutes to hours. One solution to this problem involves conjugation to carriers such as polyethylene glycol (PEG), the Fc portion of IgG, serum albumin, and other longlived macromolecules. The large carriers retard kidney filtration and hence increase plasma half-life of the attached drug. Much success has been realized thus far with PEG as the macromolecular carrier. PEG is nontoxic and nonimmunogenic, and the plasma half-life is a function of hydrodynamic size. Conjugation of drugs to PEG with molecular mass ∼40 kDa has been successfully used with peptides, nucleic acids, and small molecules and can afford half-lives of up to ∼7 d in humans; as of 2011, 10 PEGylated peptide-based drugs were approved by the Food and Drug Administration (FDA) and ∼40 were in clinical trials (1, 2) .
All of the currently marketed PEG-protein conjugates are permanently PEGylated. Attachment of large PEG moieties often reduces activity of the drug, and higher concentrations of conjugate are necessary to achieve the required biological activity. A further limitation is that permanent PEGylation is generally not applicable to small-molecule drugs because the bulky carrier usually prevents their binding to targets and cell penetration.
Recent research has focused on conjugates as releasable carriers of drugs (3) . Here, the drug is attached to the macromolecular carrier-often PEG-by a linker that is cleaved to release the native drug. An important advantage of such conjugates is that the released drug has full activity, unencumbered by the bulky macromolecular carrier. In one example, a carboxylic acid moiety of the PEG carrier and a hydroxyl group of a drug or a prodrug are connected via an ester linkage, and drug release occurs by the action of nonspecific esterases (3, 4) . The significant variability in serum esterases often leads to difficult preclinical development, unpredictable cleavage rates, and variability in drug exposure.
In the present work, we describe an approach toward releasable macromolecule-drug conjugates that overcomes many of the limitations of previously described conjugates. Here, the native, active drug is released by a hydroxide-catalyzed β-elimination reaction. Multiple linkers have been developed that have cleavage rates predetermined by the acidity of a C-H bond on the linker; the acidity is in turn controlled by electron-withdrawing groups attached to the ionizable C-H. These linkers do not require the action of hydrolytic enzymes and provide release rates with halflives ranging from hours to >1 y. Fluorenylmethoxycarbonyl linkers for PEG-drug conjugates have previously been reported that also release the active moiety by a β-elimination mechanism but they do not provide predictable and adjustable release rates (5, 6 ). The unique linkers described here enable the construction of drug conjugates having predictable, tunable release kinetics over long periods that translate from in vitro to in vivo environments.
Results
In the present work, our linkers are attached to an amine group of a ligand, i.e., a drug or prodrug, via a carbamate moiety. Simple O-alkyl carbamates are extraordinarily stable toward O-acyl-bond hydrolysis, showing half-lives of many years at physiological pH (7) ; for example, hydroxide-catalyzed hydrolysis of phenyl urethane proceeds at ∼0.1 M −1 ·h −1 (8) , which corresponds to a halflife of over a millennium for hydroxide-catalyzed cleavage at pH 7.4. However, cleavage of the O-alkyl bond of a carbamate by an alternative route results in formation of a carbamic acid and subsequent rapid generation of the amine-containing moiety. In the present work, a macromolecular carrier is attached to a linker that is attached to the drug or prodrug via a carbamate group (1 in Scheme 1); the β-carbon has an acidic C-H and also contains an electron-withdrawing "modulator" that controls the pK a of that C-H. Upon proton removal, a rapid β-elimination occurs to cleave the C-O of the linker-carbamate bond and, after loss of CO 2 , provides the free drug or prodrug and a substituted alkene, 2 (Scheme 1). The rate of drug release is proportional to the acidity (pK a ) of the proton adjacent to the modulator, and that pK a is controlled by the chemical nature of the modulator. Thus, the rate of drug release can be controlled by the nature of the modulator. 
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Model Exploratory Studies. We reasoned that the ability to modulate C-H acidities in the linkers would directly impact the rate of β-elimination, such that it could be varied over a wide time range in a predictable manner. In exploratory studies, a series of model linker scaffolds having a variety of electron-withdrawing pK a modulators-substituted aromatics, ketones, nitrile, and sulfoneswere prepared and linked via carbamate bonds to N e -2,4-dinitrophenyl-L-lysine [Lys(DNP)OH] (Scheme 2). The t 1/2 values of β-eliminative cleavage of these carbamates, 3 (Scheme 2), to form Lys(DNP)OH spanned several hours to several months at pH 7.4. That cleavage was due to β-eliminative reactions was evidenced by the widely varied half-lives consistent with the anticipated β-CH acidities and the high stability of O-benzyl-N-Lys(DNP)OH carbamate (t 1/2 > 30 y at pH 7.4), which cannot undergo O-alkyl scission. Of particular interest in this series were substituted phenylsulfone pK a modulators [3 (Scheme 2), Mod = XPhSO 2 −) because substituents on the phenyl moiety could be readily modified to alter the acidity of the β-CH and hence the rates of β-elimination.
It was also observed that, compared with R = H, when R was alkyl the rate decreased approximately twofold, whereas when R was aromatic the rate increased approximately twofold.
Scheme 2.
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Kinetic studies were performed on the β-elimination of 3 (Scheme 2), Mod = 3-NO 2 PhSO 2 −, R = H (SI Text 1). Over the pH range studied of 4.5-9.3 at 25°C, the reaction was first order in the hydroxide ion, showing k = 2.2 ± 0.5 × . Buffer catalysis was not observed at pH 8.5 and when the reaction was performed in D 2 O (potassium PO 4 , pD ∼ 7.5, 37°C) the vinyl sulfone product had ≤6% deuterium incorporated into the double bond. This result showed that H-D exchange at the β-CH was slower than the elimination and did not involve an (E1cB) R mechanism in which rapid preequilibrium carbanion formation preceded elimination; rather, the reaction involves rate-determining proton abstraction by the hydroxide ion. Thus, the β-elimination proceeds by either a concerted E 2 mechanism or the kinetically equivalent (E 1 cB) I mechanism in which carbanion formation is rate determining (9) . Here, an important practical point is that the reaction is first order in the hydroxide ion: Consequently, rates decrease 10-fold for each pH unit reduction, and conjugates may be stored for significantly longer periods at lower pH. Further, when the reaction was performed in 40% rat or mouse serum (pH 7.4, 37°C), no significant rate differences were observed.
Synthesis of Conjugates. We developed a synthetic approach for conjugates that is generally applicable to a large variety of ligands and supports (SI Text 2). As shown in Scheme 3, bifunctional linkers containing a pK a modulator were prepared with a succinimidyl carbonate on one end and an azide on the other (6) . In the present work, these modulators consist of substituted phenyl sulfones (A, Scheme 3), methyl sulfone (B, Scheme 3), morpholino sulfonyl (C, Scheme 3), N,N-diethylamino sulfonyl (D, Scheme 3) and cyano (E, Scheme 3). To synthesize these linkers, 6-azidohexanal was condensed with an appropriate anion (4) to give the alcohol 5 (Scheme 3), which was then converted to the succinimidyl carbonate 6 (Scheme 3). An analogous stable bifunctional linker, 6-azidohexyl-succinimidyl carbonate, was likewise prepared from 6-azidohexanol. Reaction of the succinimidyl carbonate with the amine moiety of a ligand provided the azidelinker carbamates 7 (Scheme 3), which were then connected via the azide to dibenzo-cyclooctyne (DBCO)-derivatized PEG by copper-free click chemistry (10) to give the desired conjugates 8 (SI Text 3, Scheme S1). Both reactions proceed rapidly and in near quantitative yield, and the conjugates can be separated from small-molecule impurities by dialysis or gel filtration. In Vitro Release Rates. We prepared and studied cleavage rates of a series of PEGylated carbamates (8) of 5-(aminoacetamido) fluorescein (5-AAF) containing either stable or releasable β-eliminative linkers (SI Text 3). As shown in Table 1 , the stable linker not possessing a modulator had a half-life for hydrolysis estimated to exceed 100 y at pH 7.4, 37°C. A series of conjugates that have 4-substituted phenyl sulfone modulators (8A, Scheme 3) showed half-lives for β-elimination that vary from 14 h to ∼2 wk. Also included are analogs that use the less electron-withdrawing modulators methyl sulfone (8B, Scheme 3), morpholinosulfonyl (8C, Scheme 3), diethylaminosulfonyl (8D, Scheme 3), and cyano (8E, Scheme 3) that expand and extend the halflife of release over a period exceeding 12 mo. A study of the cleavage rates of 8A (Scheme 3), X = CF 3 −, from 5°C to 37°C showed a 115-fold change with an activation energy of 107 kJ·mol −1 and a frequency factor of 1.9 × 10 13 s −1 (SI Text 3e). We also showed that the rate of elimination is only modestly dependent on the basicity of the aliphatic amine component of the carbamate. For example, with phenyl sulfone as the modulator, PEG conjugates 8A (Scheme 3) linked to aliphatic amines with a pK a range of ∼7.8-10.3 [5-AAF; α-DNP-LysOH, Lys (DNP)OH, Lys(DNP)-GlyOH] showed no more than twofold differences in release rate (SI Text 4i). Thus, when used to attach PEG to α-and ε-amine residues of peptides and other aliphatic amines, the release rates of these carbamates closely correspond to those described in Table 1 . This result is expected because the pK a of the carbamic acid-leaving group in the β-elimination reaction should not be greatly affected by the amine component.
Reactivity of PEG-Alkenylsulfones. The coproduct of the β-elimination is a PEGylated β-alkenyl sulfone, e.g., 2 (Scheme 1). We desired to determine the reactivity and hence the possible fate of these Michael acceptors that are anticipated to undergo either renal clearance or reaction with nucleophiles-particularly thiolsin the blood compartment. Compared with simple vinylsulfones, the reactivities of the PEGylated alkenylsulfones toward nucleophiles are expected to be attenuated by the β-alkyl group of the vinyl moiety and shielded by the large PEG moiety. Because it was unlikely that the large PEGylated alkenylsulfones could be separated from their addition products by HPLC, we studied the reactivity of corresponding labeled β-linker vinyl sulfones, formed by treatment of 6 (Scheme 3) with base and attachment to DBCO-Lys (5-FAM)OH to facilitate HPLC detection (SI Text 5); as noted above, these vinyl sulfones may be more but certainly not less reactive than their PEGylated counterparts. The phenylsulfonylsubstituted alkene was completely stable in phosphate, pH 7.4, at 37°C for at least 10 d, and only ∼4% converted in borate, pH 9.4, after 10 d, showing that its reactivity toward water was low. In contrast, we could readily detect addition products with varying concentrations of glutathione. The second-order rate constants (Table 1) correlate well with the order of reactivity of the β-elimination reactions that give rise to the vinyl sulfones, and the rates are quite slow. The largest contributor to free thiol in serum is albumin, which is present at 0.5-0.8 mM and contains ∼70% mercaptalbumin (11); assuming PEGylated alkenylsulfones are maximally present in the micromolar range in the blood compartment, the calculated half-lives of the model compounds with 0.5 mM glutathione (GSH) range from ∼50 to 1,000 h. The reactivity of free amino groups toward Michael acceptors is reportedly 200-to 400-fold slower than that of the thiol of GSH (12) , and at physiological pH most amines exist as unreactive protonated forms. Thus, although the PEGylated remnants of β-elimination could react with serum nucleophiles, the reactions are competitive with or slower than rates of renal clearance of such conjugates.
Modeling of in Vivo Pharmacokinetics. In a one-compartment model for release of drugs from macromolecule conjugates retained in the blood compartment (Fig. 1) , the drug is released from the conjugate in a first-order process with rate constant k 1 , the drug is cleared with k 2 , and the conjugate is cleared with rate constant k 3 . Using an analytical solution of the differential equations describing this model (SI Text 6), we derived Eqs. 
½Drug bol ¼ ½Drug 0 e −ðk2Þt [3] data is provided in Fig. 1 Table S1 ). Fig. 2A ) for clearance of the structurally related releasable conjugates. With all releasable conjugates, there is a brief distribution phase, followed by an elimination phase due to both conjugate clearance and linker cleavage (t 1/2,β ; k 1 + k 3 ). Structure-Activity Relationships. As in Fig. 2D , for substituted phenyl sulfones the in vitro cleavage rates (Table 1) show an excellent Hammett correlation with σ constants for substituents on the phenyl sulfone modulator reported for pK a values of substituted phenols (18) and fit the equation log k 1 = −2.08 + 1.49σ (R 2 = 0.995). Predictable, fine-tuning of in vitro β-elimination rates can thus be achieved by varying the substituent on a phenyl sulfone modulator. Fig. 2D shows a Hammett plot of in vivo k 1 for the same six releasable conjugates in rats that fit the equation log k 1 = −1.64 + 1.42σ (R 2 = 0.993). Also shown are data for four of these conjugates in mice showing log k 1 = −1.59 + 1.34σ (R 2 = 0.997), which agree well with those in rats; the two conjugates with slower release rates could not be determined in mice because of the high clearance rate (k 3 ) of the conjugates. As with the in vitro rates, in vivo release rates show the same excellent correlation with σ, but they are two-to threefold faster. This excellent structure-activity relationship, together with the availability of σ constants over 60 substituted phenols (18) , predicts that fine-tuning of in vivo β-elimination release rates should be easily attainable. From Fig. 2D , the linear free energy relationship that describes the in vivo rates of cleavage (k 1 ) of a linker with a phenyl sulfone modulator in both rodents is given by Eq. 6:
If the elimination rate constant of a stable conjugate in the test species (k 3 ) is known and is similar to that in rodents, then the elimination rate of the released drug in any species (k drug ) may be estimated as in Eq. 7,
which for phenyl sulfone modulators in this series of linkers is
Half-Life Extension of Exenatide. The utility of these linkers was demonstrated by t 1/2 extension of exenatide, a 39-aa peptide that is a potent glucagon-like peptide-1 (GLP-1) agonist (19 (Fig. 3A) . The conjugate showed an in vivo cleavage t 1/2 of 78 h and an elimination t 1/2 for released exenatide of 28 h, a 56-fold increase over the 0.5-h t 1/2 for bolus injection (21) . Assuming a clearance t 1/2 for the PEG conjugate of 7 d in humans, applying Eq. 7 to these data predicts the released exenatide would have an elimination t 1/2 of 53 h in humans. Studies with 2 mg of Exenatide once weekly have shown that the therapeutic steady-state concentration (C SS ) of exenatide in humans is ∼58-70 pM (22, 23) . To maintain exenatide >70 pM with our conjugate for 1 wk (three half-lives) in humans it would be necessary to attain a maximum concentration (C max ) of 0.5 nM exenatide. Using a volume of distribution at steady state (V SS ) of 0.2 L/kg (21) and Eq. 5, we estimate this state could be achieved by ∼12 mg/wk (170 μg·kg
) of the PEG 40kDa conjugate containing ∼1 mg exenatide. Although the t 1/2 of released exenatide could be increased using a linker with a longer cleavage t 1/2 , the dosing interval of circulating conjugates is limited by the renal clearance of the uncleaved conjugate. The t 1/2 of a drug released from a conjugate and its efficiency of utilization can be increased by reducing clearance of the conjugate over the duration of drug release; in the extreme, the t 1/2 of a drug released from a stable s.c. implant should equal the t 1/2 of the linker itself, when k 3 = 0 in Eq. 7. We coupled the N α -azido-linker exenatide 7A (Scheme 3), Mod = pClPhSO 2 −, to a DBCO-modified PEGA resin (SI Text 9). PEGA is a commercially available, amine-modified acrylamide-PEG copolymer of unknown biocompatibility. The in vitro t 1/2 for cleavage of the conjugate at pH 7.4, 37°C, was 226 h, ∼6-fold fold longer than the PEG-AAF counterpart ( Table 1 ). The hydrogel conjugate was implanted s.c. and serum exenatide levels were measured (Fig. 3B) . Over 1 wk, there is an absorption phase, k abs , with t 1/2 ∼ 4 h followed by firstorder loss of exenatide with a t 1/2 of 78 h-a 156-fold extension of the 0.5-h t 1/2 of bolus exenatide. In accord with PEG-AAF conjugates (Fig. 2D) , the in vivo cleavage is ∼3-fold faster than in vitro β-elimination. Assuming complete bioavailabilty of the released exenatide, we calculate that in humans a C max of 0.3 nM could be achieved with a single dose of ∼700 μg (10 μg/kg) exenatide, which would keep the level above its target of 70 pM for 1 wk.
Discussion
We have developed linkers that overcome limitations of those currently used in releasable drug conjugation to macromolecules. Modular heterobifunctional linkers have been designed that can at one end be readily attached to the amine group of a drug or prodrug as a carbamate and on the other to a macromolecular carrier. The linkers have an ionizable C-H in which the acidity is controlled by an electron-withdrawing pK a modulator. Upon proton abstraction the linkers undergo β-elimination to release the native, amine-containing drug or prodrug from the carrier. Thus, by controlling the acidity of the ionizable C-H by the structure of the pK a modulator, we can control the rate of drug release.
We constructed linkers possessing substituted phenyl sulfones, methyl sulfone, sulfonamides, and a cyano group as electronwithdrawing pK a modulators; these provide a set of self-cleaving linkers with preprogrammed half-lives ranging from hours to >1 y. The in vitro rates of β-elimination at pH 7.4 show an excellent structure-activity relationship with the electron-withdrawing ability of the pK a modulator, such that construction of new linkers having desired release rates should be highly predictable. We showed that the β-elimination was first order in the hydroxide ion over a wide pH range and was not significantly influenced by buffer concentration or rodent serum. Also, the reaction is highly temperature sensitive, showing an ∼100-fold lower rate at 5°C than at 37°C. Thus, rates decrease 10-fold with every pH unit reduction, and conjugates may be stored for long periods at lower pH and temperature. For example, a β- . , R 2 = 0.96; sum of conjugate and alkenylsulfone coproduct, --•--, R 2 = 0.77; released free exenatide, -■-, R 2 = 0.90; and simulated curve of exenatide injected as a bolus, ---. Points are average of duplicate determinations with an average SD of 7% for the conjugate, 6% for total PEG, and 11% for exenatide, and lines are fitted by simplex optimization of Eqs. 1 and 2 to give the best-fit values: 
eliminative linker of a prodrug with a rather low t 1/2 of 14 h at pH 7.4 and 37°C would have a half-life of ∼40 y at pH 5.0 and 5°C. We prepared circulating conjugates using PEG as a carrier and derived equations that allow simulations of in vivo C vs. T curves of remaining releasable conjugate and the drug that is released. Under specified conditions, the rate of loss of both the conjugate and the released drug from the blood compartment are the sum of the rates of conjugate clearance (k 3 ) and linker cleavage (k 1 )-i.e., k 1 + k 3 . Hence, by separately determining the rate of conjugate clearance using a stable linker, one can determine the rate of linker cleavage in vivo. The linear free energy correlation of the in vivo rates with electron-withdrawing abilities of the pK a modulator is excellent and parallels the structure-activity relationship of in vitro cleavage; thus, in vivo release rates are also predictable and can be described by a simple linear free energy relationship. Simulations show that, with a given rate of conjugate clearance, the concentration of the free drug released from its carrier and its in vivo halflife can be controlled by the conjugate concentration and the t 1/2 for conjugate cleavage. To our knowledge, no other releasable linker platform offers such structure-based in vivo predictability.
With slowly cleaving linkers, the half-life of a circulating conjugate and released drug can be limited by the rate of renal clearance of the conjugate, which varies significantly among species. For example, the half-life of drug conjugates of branched PEG 40kDa is ∼24 h in mice, 48 h in rat, and 7 d in humans. Thus, animal models in which conjugate clearance is rapid compared with linker cleavage are imperfect models for predicting pharmacokinetics in species where conjugate clearance is relatively slow. However, because the rate of cleavage (k 1 ) seems species independent, translation of drug elimination rates (k 1 + k 3 ) in one species to another species can be made knowing the conjugate clearance rates (k 3 ). Indeed, we describe a simple linear free energy equation that allows estimation of released drug and conjugate half-lives in rodents and, although not tested, in any species. Knowledge of other pharmacokinetic parameters, such as free drug clearance rate and volume of distribution, should allow a rather complete description of parameters commonly used to profile in vivo pharmacokinetics.
As an illustration of the utility of these linkers, we have shown that a releasable PEG-exenatide conjugate increased the half-life of serum exenatide in rats by ∼50-fold. Although this increase can be lengthened by use of more slowly cleaving linkers, the half-life extension is ultimately limited by the renal clearance rate of the carrier. The effective half-life of a drug released from a conjugate can be prolonged to equal the t 1/2 of the linker by using a carrier that does not clear over the duration of drug release, such as a stable s.c. implant. We prepared a hydrogel-exenatide conjugate and showed that after s.c. implantation exenatide is slowly released into circulation and shows a 150-fold half-life extension. Either the circulating PEG or fixed implant formats should suffice for an efficient, once-weekly dosage form of exenatide. Moreover, we speculate that conjugation of potent drugs to an appropriate hydrogel implant via β-eliminative linkers with very slow cleavage rates could allow once-a-month administration.
In addition to increasing drug duration, other benefits are achieved by use of the β-eliminative linkers described here. First, compared with bolus dosing, C max is lowered, which can reduce off-target side effects for some drugs. Second, the pharmacokinetics of drugs used in combination can be coordinated to optimize efficacy; that is, two or more drugs can be provided the same or different effective half-lives. Finally, the platform is ideal for delivering injectable therapeutics by low-dose, long-exposure "metronomic" chemotherapy (24)-an increasingly important approach for long-term treatment of cancer with subtoxic, antiangiogenic doses of therapeutic agents.
The lack of enzyme dependence on release from these linkers suggests that the β-eliminative mode of releasable conjugation provides a more stable, predictable platform for drug delivery than those requiring enzyme-mediated release. Thus, the use of self-cleaving β-eliminative linkers should provide a smaller range of interspecies and interpatient variability in the exposure of the released drugs. Finally, the effective half-life of a released drug can be further prolonged by using a carrier with a slower clearance-the extreme being a carrier with no clearance over the duration of drug release. Further studies of the use of the longlived β-eliminative linkers described here with appropriate noncirculating s.c. implants are in progress.
Materials and Methods
The source of specialized materials is provided along with their use in SI Text. Detailed synthetic and conjugation procedures are described as well as HPLC, NMR, and MS analytical methods. In vitro kinetic procedures using HPLC methodologies are provided. In vivo pharmacokinetic methods and results are described in SI Text 7 and SI Text 8, and complete pharmacokinetic data on PEG-fluorescein conjugates in rats and mice are given in Table S1 . ethyl-O′-succinimidyl carbonate. Pyridine (160 μL) was added dropwise to a stirred solution of (3-nitrophenyl)sulfonyl)ethanol (231 mg, 1.0 mmol) and triphosgene (500 mg, 1.7 mmol) in 15 mL of anhydrous tetrahydrofuran (THF). The resulting suspension was stirred for 10 min and then filtered and concentrated to provide the crude chloroformate as an oil. The chloroformate was redissolved in 15 mL of dry THF and treated successively with N-hydroxysuccinimide (350 mg, 3.0 mmol) and pyridine (250 μL) for 10 min. The mixture was concentrated, and the residue was diluted in dichloromethane and washed sequentially with water, 1 M citric acid, water, and brine. After drying over MgSO 4 , the solution was filtered and evaporated to provide a yellow oil that crystallized on standing. The solid mass was triturated with 1:1 ethyl acetate/ hexane, and the solid was collected and dried to provide 268 mg (72%) of product. 94H, dd) . Thus, when the β-elimination was performed in D 2 O, there was no indication of deuterium incorporation at the vinyl α-carbon, and the ratio of β-to α-protons was 2:0.94, indicating ≤6% exchange.
Supporting Information
2. Synthesis of Hetero-Bifunctional Linkers. a. 6-Azidohexanal. A mixture of 6-chloro-1-hexanol (25 g, 183 mmol) and sodium azide (32.5 g, 500 mmol) in 200 mL of water was heated at reflux for 20 h and then cooled to ambient temperature and extracted three times with ethyl acetate. The combined extracts were washed with brine, dried over MgSO 4 , filtered, and concentrated to yield 25.3 g (177 mmol, 97%) of 6-azido-1-hexanol, which was used without further purification. Solid trichloroisocyanuric acid (4.3 g, 18.5 mmol) was added in small portions to a vigorously stirred mixture of 6-azido-1-hexanol (7.15 g, 50 mmol), TEMPO (0.08 g, 0.5 mmol), and sodium bicarbonate (5.0 g, 60 mmol) in dichloromethane (100 mL) and water (10 mL). The mixture was stirred for an additional 30 min after addition and then filtered through a pad of Celite. The organic phase was separated and washed successively with saturated aqueous NaHCO 3 and brine and then dried over MgSO 4 , filtered, and concentrated to provide 6-azidohexanal (5.8 g, 41.1 mmol, 82%), which was used without further purification.
1 H-NMR (400 MHz, d 6 -DMSO): δ 9.66 (1H, t, J = 1.5 Hz), 3.31 (2H, t, J = 6.9 Hz), 2.43 (2H, dt, J = 1.5, 7.2 Hz), 1.55 (4H, m), 1.32 (2H, m). b. 1-(Phenylsulfonyl)-7-azido-2-heptanol. A 1.6-M solution of nbutyllithium (3.1 mL, 5.0 mmol) in hexane was added dropwise to a stirred solution of phenyl methyl sulfone (780 mg, 5.0 mmol) in anhydrous THF (15 mL) previously cooled to −78°C. After addition, the cooling bath was removed and the mixture was allowed to warm slowly to 0°C over ∼30 min. The mixture was then cooled to -78°C, and 6-azidohexanal (0.78 g, 5.5 mmol) was added. After stirring for 15 min, the cooling bath was removed and the mixture was allowed to warm. At the point where the mixture became clear, 5 mL of saturated aq. NH 4 Cl was added and the mixture was allowed to continue warming to ambient temperature. The mixture was diluted with ethyl acetate and washed successively with water and brine and then dried over MgSO 4 , filtered, and evaporated to provide the crude product as an oil. Chromatography on a silica gel using a step gradient of ethyl acetate in hexane (0%, 25%, 50%) provided the purified product as a pale yellow oil (1.25 g, 4.25 mmol, 85%). Pyridine (160 μL) was added dropwise to a stirred solution of 1-(phenylsulfonyl)-7-azido-2-heptanol (297 mg, 1.0 mmol) and triphosgene (500 mg, 1.7 mmol) in 15 mL of anhydrous THF. The resulting suspension was stirred for 10 min and then filtered and concentrated to provide the crude chloroformate as an oil. The chloroformate was redissolved in 15 mL of dry THF and treated successively with N-hydroxysuccinimide (350 mg, 3.0 mmol) and pyridine (250 μL) for 10 min. The mixture was then concentrated, and the residue was redissolved in ethyl acetate. After washing successively with 0.1 N HCl, water, saturated aq. NaHCO 3 , water, and brine, the solution was dried over MgSO 4 , filtered, and evaporated. The crude succinimidyl carbonate was chromatographed on a silica gel using a step gradient of ethyl acetate in hexane [0%, 25%, 50%, 75% (vol/vol)], providing the product as a colorless oil that crystallized on standing (391 mg, 0.89 mmol, 89% ), consistent with the reported and TNBS analysis of the starting four-branched mPEG amine (GL400-PA, 88% terminal amine activity). An analogous method was used to prepare linear mPEG 40kDa -DBCO. b. PEG-linker-fluorescein conjugates. A 25-mM solution of the linkersuccinimidyl carbonate (compound 4) in DMSO (100 μL, 2.5 μmol) was added to a 10-mg/mL solution of 5-(aminoacetamido) fluorescein (Invitrogen) in DMSO (115 μL, 2.8 μmol). After 1 h at ambient temperature, the mixture was analyzed by reversedphase HPLC, indicating complete consumption of azide-linkerhydroxysuccinimide ester (HSE) and formation of a single fluorescein-containing product. This solution was added to a solution of four-branched mPEG-DBCO (50 mg, 1.25 μmol) in 0.5 mL of THF and the mixture was kept at ambient temperature for 24 h. HPLC analysis at 440 nm indicated complete reaction as judged by the stability and ratio of peak areas of the conjugate and remaining linker-fluorescein. The mixture was diluted with 1 mL of water and then dialyzed overnight against methanol, using a SpectraPor (Spectrum Laboratories) 2 membrane (molecular mass cutoff 12-14 kDa). Evaporation followed by rinsing of the resulting residue with MTBE provided partially purified conjugate, which was dissolved in 1 mL of 10 mM sodium acetate, pH 5, and chromatographed on a PD-10 sizing column (GE HealthCare) using 10 mM sodium acetate, pH 5. The macromolecular fraction was collected, and the concentration was determined by the UV absorbance of the fluorescein component (ε = 80,000, 494 nm) after dilution of an aliquot into 0.1 M borate buffer, pH 9.3. TNBS analysis showed the absence of free amine. c. TNBS assay for determination of amine concentration. This assay is a modification of a reported method (1) . To each of eight 1-mL cuvettetes was added 0.5 mL of 1.5 mM TNBS in 0.1 M Na borate, pH 9.3. To four cuvettetes was added 0.5 mL of 0.1 M Na borate, pH 9.3 (blanks) and to the remaining four cuvettetes was added 0.5 mL of the amine samples (≥50 mM) in Na borate. The OD was determined at 420 nm until the reading was stable (∼35 min). The SD, LOD (3 × SD) and LOQ (10 × SD) were determined for the blanks, and amine concentration was calculated by subtracting the average blank OD from the sample OD. For amine samples that absorb at 420 nm, two of the blanks contained the amine samples at identical concentration to the test samples but without TNBS. The average absorbance of the amine-containing blank plus the TNBS blanks was subtracted from the sample OD after TNBS reaction. d. In vitro kinetics of β-elimination of PEG-AAF conjugates. Kinetic assays containing ∼40 μM PEG conjugate in 100 mM buffer (Hepes, pH 7.5; bicine, pH 8.5; or Na borate, pH 9.3) were incubated at 37°C. At intervals over at least three half-lives, 30-μL aliquots were removed, quenched with 33 μL of 0. ; thus, the β-eliminative cleavage rate is retarded some 115-fold at 5°C compared with 37°C. A plot of Ln k obsd vs. 1/T gave the equation ln(k) = −12,872(1/T) + 38.8 (R 2 = 0.985), allowing calculation of the activation energy Ea = 107 kJ·mol −1 and frequency factor A = 1.9 × 10 13 s −1 .
4. Preparation and β-Elimination of mPEG-Linked DNP-Lysines. a. N a -DNP-L-lysine trifluoroacetate. Diethylamine (1.0 mL, 10 mmol) was added to a solution of Fmoc-Lys(Boc)-OH (Sigma; 235 mg, 0.5 mmol) in 5 mL of N,N-dimethyl formamide (DMF). The mixture was stirred for 30 min and then diluted with 10 mL of ether. The resulting white precipitate was collected by centrifugation, washed twice with ether, and air dried. The solid was dissolved in 10 mL of 0.1 M NaHCO 3 , and 2,4-dinitro-fluorobenzene (125 μL, 1.0 mmol) and methanol (1 mL) were added. After stirring for 16 h, the mixture was washed three times with ethyl acetate. The aqueous phase was acidified with 1 N HCl and extracted with ethyl acetate. The extract was dried over MgSO 4 , filtered, and evaporated to provide a yellow glass, which was dissolved in 5 mL of trifluoroacetic acid. After 10 min, this solution was added slowly to 100 mL of ether with stirring, giving a bright yellow precipitate. The precipitate was collected, washed with ether, and dried to provide N a -DNP-L-lysine trifluoroacetate (150 mg, 38% overall yield). 43 mmol) in 13 mL of acetonitrile was added over 5 min to a mix of N e -(2,4-dinitrophenyl)-L-lysine hydrochloride (Sigma; 0.500 g, 1.43 mmol) in 7 mL of water, 1 N NaOH (2.86 mL, 2.86 mmol), and 1 M NaHCO 3 (2.86 mL, 2.86 mmol). The reaction solution was stirred at ambient temperature for 1 h at which time analysis by TLC (100% ethyl acetate) showed completion of the reaction. The solution was adjusted to pH 3 with 1 N hydrochloric acid solution and extracted with ethyl acetate. The extract was washed with water and saturated sodium chloride solution, dried over MgSO 4 , and then filtered and evaporated to give a sticky orange foam (0.737 g) that was purified using a Thomson Instruments Single-Step silica gel column (25 g) and eluted with 50% ethyl acetate/50% hexanes followed by 100% ethyl acetate to produce the title compound as a yellow oil (0.540 g, 1.01 mmol, 70%).
To a stirred solution of Fmoc-Lys(DNP)-OH (0.300 g, 0.561 mmol), glycine tert-butyl ester hydrochloride (0.113 g, 0.674 mmol), 1-hydroxybenzotriazole hydrate (0.113 g, ∼0.674 mmol), and N-methylmorpholine (1.85 mL, 1.68 mmol) in N,N-dimethylformamide (3 mL) was added N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide (0.114 g, 0.674 mmol). The solution was stirred for 1 h at room temperature at which time analysis by TLC (100% ethyl acetate) showed consumption of the starting material and the appearance of a new less polar product spot. The solution was diluted with water (30 mL) and extracted with ethyl acetate (3 × 15 mL). The organic extracts were combined, washed with water, 5% KHSO 4 solution, water, and saturated sodium chloride solution, and dried over MgSO 4 . The solvent was evaporated to give a yellow oil (0.371 g) that was purified using a Thomson Instruments Single-Step silica gel column (12 g ) and eluted with 40% ethyl acetate/60% (vol/vol) hexanes followed by 50% ethyl acetate/50% (vol/vol) hexanes to furnish Fmoc-Lys (DNP)Gly-O t Bu as a yellow oil (0.307 g, 0.471 mmol, 84%). H 2 N-Lys(DNP)Gly-OH (0.051 g, 0.126 mmol) was suspended in water (796 μL) and then 1 N sodium hydroxide solution (252 μL, 0.252 mmol) and 1 M sodium hydrogen carbonate solution (252 μL, 0.252 mmol) were added to give a yellow solution. To this solution was added a solution of the NHS carbonate (0.058 g, 0.132 mmol) in acetonitrile (1.3 mL) over 5 min. The reaction solution was stirred at ambient temperature for 2 h. The pH was adjusted to pH 4 with 6 N HCl and then loaded onto a C 18 BondElut column (1 g; Varian). The column was washed with water followed by 1:1 water/methanol, and then the product was eluted with 100% (vol/ vol) methanol. The solvent was evaporated to give the azide as a yellow glass (0.060 g), which was used without further purification. h. Conjugation to mPEG 40kDa . A solution of the azide (2 mg, 2.95 μmol) in acetonitrile (500 μL) was added to a stirred solution of linear mPEG 40kDa -DBCO (50 mg, 1.25 μmol) in acetonitrile (500 μL). The solution was stirred at ambient temperature for 7 h at which time analysis of the solution by HPLC showed disappearance of the 291-and 309-nm absorbance maxima in the PEG signal. The solution was diluted with methanol (5 mL) and dialyzed [molecular weight cut-off (MWCO): 12-14 K] against water and then methanol. The retentate was concentrated to give a solid that dissolved in tetrahydrofuran (1 mL) and precipitated by addition to a stirred solution of methyl tert-butyl ether (15 mL). The precipitate was allowed to stand for 1 h and was then collected by filtration, washed with methyl tert-butyl ether (2 × 10 mL), and dried under vacuum to give a pale yellow solid (42 mg, 84%). i. Release kinetics. Solutions of the conjugates (0.4 mM) in 0.1 M Hepes, pH 7.4, at 37°C were followed by HPLC. Aliquots of 20 μL were periodically injected onto a C4 reversed-phase column equilibrated in 80:20 H 2 O/CH 3 CN/0.1% CF 3 CO 2 H, and the column was eluted with a gradient to 100% CH 3 CN/0.1% CF 3 CO 2 H over 10 min. Peak areas at 356 nm were used to determine released product (P) and remaining conjugate (C). First-order rates and half-lives were determined from plots of ln(1 − P/(P + C)) vs. time to be (i) alpha-linked Lys(DNP), k = 0.0039 h bonate (44 mg, 0.1 mmol) in 1.0 mL of 0.1 M triethylamine in acetonitrile was kept at ambient temperature. The reaction was monitored by HPLC and was complete after 1 h. After evaporation of the solvent, the mixture was redissolved in 10 mL of ethyl acetate and washed sequentially with water and brine. After drying over MgSO 4 , the mixture was filtered and evaporated to dryness to provide the product (25 mg, 89%). Other azido alkenylsulfones were prepared according to the same method:
7-Azido-1-(4-chlorophenylsulfonyl)-1-heptene (reaction time, 0.5 h). 138 μmol; AnaSpec) in 2 mL of DMF, followed by 0.4 mL of water. The dark red mixture was kept for 4 h at ambient temperature, at which time the reaction was judged to be complete by HPLC. The mixture was acidified with 6 N HCl and the resulting yellow solution was diluted to 10 mL with water and washed twice with ethyl acetate. The aqueous phase was loaded onto a C18 BondElut extraction column, which was washed with water followed by 1:1 acetonitrile/water to elute the yellow product. After evaporation of product-containing fractions, the orange solid was triturated with acetonitrile and dried to provide the H-Lys(5-FAM)-OH hydrochloride (57 mg, 80%) as an orange powder. This material showed a single peak by reversed-phase HPLC analysis.
A solution of DBCO-NHS (24 mg, 50 μmol; Click Chemistry Tools) in 1 mL of DMF was added to a solution of N e -(Fluorescein-5-carboxamide)-L-lysine (32 mg, 60 μmol) in 1 mL of 0.2 M aqueous NaHCO 3 . After 3 h at ambient temperature, HPLC analysis indicated complete consumption of the DBCO-NHS. The mixture was acidified to pH 3 using 1 N HCl, diluted to 5 mL with 50% methanol in water, and loaded onto a C18 BondElut extraction column. The column was washed with water, then 50% (vol/vol) methanol/water, and then methanol. Evaporation of the methanol fraction yielded the product (44 mg, 50 μmol, 100%), which showed a single peak by reversed-phase HPLC analysis. UV (MeOH) λ max = 484, 457, 288, 307 and (H 2 O, pH 8.5) 496, 290. c. Conjugation of azido-alkenylsulfones to DBCO-Lys(5-FAM)-OH. A solution of 7-azido-1-(phenylsulfonyl)-1-heptene (25 mM in CH 3 CN, 100 μL, 2.5 μmol) was mixed with a solution of DBCOLys(5-FAM)-OH (25 mM in CH 3 OH, 100 μL, 2.5 μmol). HPLC analysis after 2 h showed constancy of product indicated complete reaction and loss of DBCO absorbance at 290 nm. The mixture was diluted into 1 mL of 20% (vol/vol) CH 3 CN in H 2 O (vol/vol) containing 0.1% CF 3 CO 2 H and loaded onto a 0.5 g BondElut C 18 column. The column was washed successively with 2 mL each of 30%, 40%, 50%, and 60% (vol/vol) CH 3 CN in H 2 O containing 0.1% CF 3 CO 2 H. The product fraction was evaporated to dryness and then redissolved in 2.0 mL of 0.1 M Hepes, pH 7.6. The product was quantitated by dilution of a 10-μL aliquot into 990 μL of 0.1 M borate, pH 9.3, and measuring the absorbance at 497 nm (ε = 80,000 M
). Yield = 1.5 μmol (60%) of a compound showing a single peak by HPLC.
Other azido alkenylsulfones listed below were conjugated to DBCO-Lys(5-FAM)-OH according to the same method:
7-Azido-1-(4-chlorophenylsulfonyl)-1-heptene (1.5 μmol, 60%), 7-Azido-1-(4-methoxyphenylsulfonyl)-1-heptene (1.4 μmol, 56%), 7-Azido-1-(2,4,6-trimethylphenylsulfonyl)-1-heptene (1.3 μmol, 52%), and 7-Azido-1-(methylsulfonyl)-1-heptene (1.6 μmol, 64%).
d. Kinetics of GSH addition to vinylsulfones. A GSH stock was prepared by dissolving reduced glutathione (614 mg; Sigma) and Hepes (240 mg) in 5 mL of water and 1 mL of 10 mM disodium EDTA. The pH was adjusted to 7.62 at ambient temperature (pH 7.4 at 37°C) with NaOH, and then the solution was brought to 10.0 mL with water. Assay of thiol content using 5,5′-dithiobis-(2-nitrobenzoic acid) (DTNB) indicated a stock concentration of 195 mM GSH. This stock was then diluted into 0.1 M Hepes, pH 7.62, to produce working stocks that were 2× the final concentration of GSH in a reaction.
For kinetic experiments, a solution of the conjugated alkenylsulfone (0.3 mM) in 0.1 M Hepes, pH 7.62 (500 μL total volume) was brought to 37°C in a 1.5-mL Teflon-lined screw cap target vial, and 500 μL of a 2× solution of GSH in 0.1 M Hepes, pH 7.62, was added to give a final solution of 2.0-100 mM, depending on the rate of reaction. The vial was kept at 37°C in the HPLC autosampler, and 20-μL injections were made periodically onto a reversed-phase column equilibrated in 20% CH 3 CN/H 2 O (0.1% CF 3 CO 2 H). A gradient to 100% CH 3 CN (0.1% CF 3 CO 2 H) over 8 min was used to separate the glutathione adduct from the alkenylsulfone. Reduction in peak areas at 440 nM was used to determine percentage of reaction. 
where k 1 is the release rate constant of drug from the polymerdrug conjugate, k 2 is the elimination rate constant of drug, and k 3 is the elimination rate constant of conjugate.
[C] is the concentration of the polymer-drug conjugate in blood described by Eq. S1, which is solved to give Eq. S2:
[D] is the concentration of drug in blood described by Eq. S3:
Substitution of k 1 [C] in Eq. S3 by Eq. S2 gives Eq. S4, which is rearranged to differential Eq. S5:
As the initial concentration of drug is zero, the solution to Eq. S5 is Eq. S6:
For drugs with short half-lives conjugated to long-lived conjugates, k 2 >> (k 1 + k 3 ), such that Eq. S6 can be simplified to Eq. S7 once the system has reached steady state:
Comparison of Eq. S2 and Eq. S7 shows that once steady state is reached for release of drugs with short half-lives from long-lived conjugates, both conjugate and free drug disappear from the system with t 1/2 = ln (2) Table S1 . 3 . A solution of DBCO-NHS in CH 3 CN (50 mg/mL, 1.0 mL, 0.10 mmol) was added and the mixture was kept for 30 min. After adjusting to pH 4 with 1 N HCl, the mixture was extracted with ethyl acetate. The extract was washed with water and brine and then dried with MgSO 4 , filtered, and evaporated. The crude product was purified on a silica gel, using a step gradient of 1:1 ethyl acetate/hexane, ethyl acetate, 10% methanol/ethyl acetate, and 10% methanol/ ethyl acetate/1% (vol/vol) acetic acid. Product-containing fractions were combined and evaporated to a yellow glass, which was washed with MTBE and then dissolved in 10 mL of methanol. After addition of 10 mL of water, the cloudy mixture was applied to a BondElut C18 column, which was then washed with a step gradient of 50%, 60%, 70%, 80%, and 100% methanol in water.
The product was eluted in the 80-100% methanol fraction, which was evaporated to provide the product [70 μmol by UV (70%)]: λ max = 419 (MeOH, ε = 44,500 M −1 ·cm
A solution of GL4-400PA (250 mg, 6.25 μmol), DBCO-Lys(DEAC)-OH (1.0 mL of a 14-mM solution in THF, 14 μmol), and N-hydroxysuccinimide (300 μL of a 100-mM solution in THF, 30 μmol) in 3 mL of THF was treated with 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride (300 μL of a 100-mM solution in DMF, 30 μmol). After 16 h, additional aliquots of N-hydroxysuccinimide (300 μL, 30 μmol), EDC (300 μL, 30 μmol), and triethylamine (10 μL, 70 μmol) were added and the reaction was kept an additional 4 h. After evaporation of the solvent, the residue was dissolved in water and dialyzed (10-to 12-kDa membrane cutoff) sequentially against 10 mM NaHCO 3 , water, and methanol. The dialysate was evaporated and then dissolved in 2 mL of THF and precipitated by addition to 10 mL of MTBE. The precipitate was collected and dried to provide 230 mg of the product (90%) as a yellow powder. e. Azido-linker exenatides. Fmoc-Tentagel Rink amide resin (0.17 Meq/g) was used to synthesize protected exenatide, using standard Fmoc/ t Bu chemistry. The resin was allowed to swell in dichloromethane and then washed with DMF. Fmoc groups were removed using piperidine. Coupling steps were performed using O-Benzotriazole-N,N,N′,N′-tetramethyl-uronium-hexafluoro-phosphate (HBTU) and N-methylmorpholine in DMF. After removal of the final Fmoc group and washing, the resin was treated with 3 M eq (on the basis of resin substitution) of the azido-linker-HSE (described in 2c) and 3 M eq of N,N-diisopropyl-ethylamine in DMF. Reaction progress was followed by ninhydrin test. After 2 h, the resin was washed with methanol and ether and then dried. Cleavage and deprotection of the product used a mixture of TFA and triisopropylsilane and water for 4 h. The crude product was then precipitated with ether and purified by HPLC, using a Supelco C18 column (21.2 mm × 150 cm) and a gradient of water and acetonitrile and 0.1% trifluoroacetic acid. The purified products were characterized by LC/MS: (1-50 nM). HPLC-MS/MS analyses were carried out on a Sciex API-5500 mass spectrometer coupled with a Shimadzu HPLC system. The Shimadzu HPLC system consisted of two LC-30AD HPLC pumps and a SIL-30AC autosampler with a 100-μL loop installed. The chromatographic separations were achieved on a Jupiter (Phenomenex) 5-μm C18, 300 Å, HPLC column, 2.0 × 150 mm, with mobile phase gradients. The mass spectrometer was operated in positive electrospray ionization mode and the resolution setting used was the unit for both Q1 and Q3. The multiple-reactions monitoring (MRM) transition was m/z = 838.3 and 396.2 for exenatide and m/z = 635.7 and 249.0 for the internal standard. Peak-area integrations were performed using Analyst software (version 1.5.2) from AB Sciex.
9. Hydrogel PEGA-Exenatide Conjugates. a. DBCO-sulfoNHS ester (2).
DBCO acid (41 mg, 105 μmol) in 131 μL DMF, sulfoNHS (105 μmol, 22.8 mg) and N,N'-dicyclohexylcarbodiimide (23.8 mg, 115 μmol) in 131 μL DMF were combined and mixed for 19 h at room temperature. The mixture was kept at 4°C for 2.5 h and centrifuged at 16,000 × g for 10 min. The supernatant was collected, the pellet was washed three times with 200 μL DMF, and the washes were combined with the supernatant. The DBCO-sulfoNHS was precipitated by addition of 30 mL of EtOAc. After 1 h the precipitate was collected by centrifugation at 2,000 × g for 10 min and washed twice with 20 mL EtOAc followed by three times with 15 mL ethyl ether. The pellet was collected and dried to provide DBCO-sulfoNHS ester (50.2 mg, 85.3 μmol, 81.2%). b. Preparation of PEGA-DBCO. The amine-derivatized hydrogel PEGA (1 mL, 34 μmol amine; 150-300 μm; Novabiochem) was combined with DBCO-sulfoNHS ester (24.2 mg, 41 μmol) in 1.4 mL 100 mM Hepes, pH 7.5. The reaction was mixed end-over-end until the loss of DBCO absorbance (309 nm) in solution stabilized. The supernatant was collected and the resin was washed four times with 0.1 M Hepes, pH 7.5, with 1 M NaCl followed by four times with 0.1 M Hepes, pH 7.5. The concentration of unreacted DBCO-sulfoNHS determined from the A 309 (ε = 13,448) of the combined supernatant and washes indicated 100% reaction of the amino groups of PEGA to give a DBCO content of 34 μmol/mL gel. The resin was capped by reaction with 5.8 mg (37 μmol) of acetyl-HSE in 0.6 mL of 1:1 MeOH/0.1 M Hepes, pH 7.5, for 2 h. The resin was washed sequentially with 5 mL each of 0.25 M and 0.1 M Hepes, pH 7.5; 3 mL each of 25%, 50%, and 75% MeOH/ 0.1 M Hepes, pH 7.5; and 3 mL 100% MeOH. c. Preparation of PEGA-linker-exenatide conjugate. A reaction solution was prepared containing 300 μL of PEGA-DBCO (10.2 μmol DBCO) and 2.3 μmol (10.5 mg) azido-linker(ClPhSO 2 )-exenatide in 1 mL of 200 mM Mes, pH 6.0. After the loss of absorbance at 280 nm in the supernatant stabilized, the supernatant was removed and the resin washed with 7 × 500 μL of 200 mM Mes, pH 6.0. The supernatant and washes were combined and the concentration of unreacted exenatide was determined by A 280 (ε = 5,500). The reaction consumed 90% of the exenatide to give PEGA-exenatide with ∼7 nmol exenatide per microliter resin. d. Rat pharmacokinetics of PEGA-exenatide conjugates. The PEGAexenatide resin (∼300 μL) was washed with sterilized 3 × 1 mL 70% EtOH/50 mM NaOAc, pH 5.0, and then 3 × 1 mL of sterilized 10 mM NaOAc, pH 5.0, and placed in 500 μL of sterile 50% glycerol/10 mM NaOAc, pH 5.0, solution. The 800-μL suspension was administered s.c., using an 18-gauge needle, in two equal volumes to the right and left flanks of cannulated male Sprague-Dawley rats. Serum samples (∼250 μL) were obtained at 0, 1, 2, 4, 8, 24, 48, 72, 120, and 168 h. e. Analysis of serum exenatide. Mass spectral analysis of exenatide in serum was performed as described above. 
